Atividade antiparasitária de compostos sintéticos contra tripanotiona redutase de Leishmania amazonensis: estudo in silico e in vitro

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Universidade Federal de Juiz de Fora (UFJF)

DOI

Abstract

Leishmaniasis is caused by protozoa of the genus Leishmania and is considered a neglected tropical disease due to its high incidence in regions with low socioeconomic development. The disease occurs in 98 countries and puts more than 350 million people at risk of infection worldwide. Tegumentary leishmaniasis, specifically, causes cutaneous and mucosal lesions that, if not properly treated, can lead to permanent deformities and severely impact individuals' quality of life. Pharmacological treatment remains a challenge for healthcare professionals due to its toxicity and the emergence of antiparasitic resistance. In this context, the trypanothione reductase (TR) enzyme emerges as a promising target for new therapies, as it plays an essential role in the parasite's antioxidant defense, making it vulnerable to specific inhibitors. The objective of this study was to evaluate the in silico and in vitro antiparasitic potential of compounds from a public library against the trypanothione reductase enzyme of L. amazonensis. The research involved virtual screening using the complete The Brazilian Compound Library (BraCoLi), which contains 1,176 compounds. In vitro tests were performed with compounds belonging to three chemical groups: L-glutamine, glucosamine, and papulacandin D derivatives. Among the results obtained, two chemical groups stood out for presenting promising results. In vitro promastigote assays, the papulocandin-D derivative BR010034 showed an IC50 of 82.78 μM, indicating anti-Leishmania activity. The L-glutamine derivative BR010032 demonstrated a reduction in LaTR enzymatic activity (63.9% inhibition). In silico pharmacokinetic profile analyses showed potential for good oral absorption of the latter. Regarding cytotoxicity against human cell lines, compound BR010032 showed a safer profile compared to BR010034, which demonstrated higher cellular toxicity. In conclusion, both compounds BR010034 and BR010032 showed anti-Leishmania activity, with BR010032 standing out for its balance between efficacy and safety, making it a promising option for the development of new therapeutic alternatives.

Description

Citation

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Except where otherwise noted, this item's license is described as Acesso Aberto